{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:01:19Z","timestamp":1790791279630,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016492","name":"Kiniksa Pharmaceuticals Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cardfail.2026.03.010","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:52:56Z","timestamp":1778572376000},"page":"877-887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Leveraging Interleukin-1 Blockade as a Therapeutic Strategy for Cardiac Sarcoidosis: Rationale and Design for the RandomizEd PhAse II TrIal of Rilonacept in Subjects With Cardiac Sarcoidosis (REPAIR-CS)"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9202-0233","authenticated-orcid":false,"given":"ANDREW N.","family":"ROSENBAUM","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANJALI","family":"WAGLE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"COURTNEY L.","family":"MEUTH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHELDON","family":"WANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOHN F.","family":"PAOLINI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MELANIE A.","family":"BRATCHER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PANITHAYA","family":"CHAREONTHAITAWEE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NISHA A.","family":"GILOTRA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2026.03.010_bib0001","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.hrthm.2014.03.043","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis","volume":"11","author":"Birnie","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0002","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1440-1827.1993.tb01148.x","article-title":"Pathological studies on sarcoidosis autopsy: epidemiological features of 320 cases in Japan","volume":"43","author":"Iwai","year":"1993","journal-title":"Acta Pathologica Japonica"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0003","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.011522","article-title":"Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study","volume":"131","author":"Kandolin","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0005","doi-asserted-by":"crossref","first-page":"e1197","DOI":"10.1161\/CIR.0000000000001240","article-title":"Diagnosis and management of cardiac sarcoidosis: a scientific statement from the American Heart Association","volume":"149","author":"Cheng","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0006","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cardfail.2021.06.016","article-title":"Sarcoidosis-related cardiomyopathy: current knowledge, challenges, and future perspectives: State-of-the-Art Review","volume":"28","author":"Gilotra","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0007","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jjcc.2013.07.007","article-title":"Recovery of atrioventricular block following steroid therapy in patients with cardiac sarcoidosis","volume":"62","author":"Yodogawa","year":"2013","journal-title":"J Cardiol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0008","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jcmg.2023.05.017","article-title":"Prospective analysis of immunosuppressive therapy in cardiac sarcoidosis with fluorodeoxyglucose myocardial accumulation: the PRESTIGE study","volume":"17","author":"Morimoto","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0009","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ahj.2019.10.003","article-title":"Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT)","volume":"220","author":"Birnie","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0010","doi-asserted-by":"crossref","first-page":"512A","DOI":"10.1016\/j.chest.2016.08.526","article-title":"Multicenter experience with mycophenolate mofetil in cardiac sarcoidosis","volume":"150","author":"Fussner","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0011","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.cardfail.2021.06.010","article-title":"Management of cardiac sarcoidosis using mycophenolate mofetil as a steroid-sparing agent","volume":"27","author":"Griffin","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0012","doi-asserted-by":"crossref","first-page":"a3054","DOI":"10.1016\/j.chest.2023.07.2002","article-title":"Methotrexate vs mycophenolate mofetil in the treatment of cardiac sarcoidosis: a comparison of therapeutic effect and clinical outcomes","volume":"164","author":"Veglia","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0013","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2021.02.022","article-title":"The effectiveness and safety of infliximab in cardiac sarcoidosis","volume":"330","author":"Bakker","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0014","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.amjcard.2019.07.067","article-title":"Infliximab for refractory cardiac sarcoidosis","volume":"124","author":"Harper","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cardfail.2020.08.013","article-title":"Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of cardiac sarcoidosis: a multicenter experience","volume":"27","author":"Gilotra","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.676407","article-title":"Case Report: TNF\u03b1 antagonists are an effective therapy in cardiac sarcoidosis","volume":"8","author":"Stievenart","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010952","article-title":"Long\u2010term corticosteroid\u2010sparing immunosuppression for cardiac sarcoidosis","volume":"8","author":"Rosenthal","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0018","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00449-2021","article-title":"Cardiac sarcoidosis: systematic review of the literature on corticosteroid and immunosuppressive therapies","volume":"59","author":"Stievenart","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0019","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cardfail.2019.02.018","article-title":"Serial cardiac FDG-PET for the diagnosis and therapeutic guidance of patients with cardiac sarcoidosis","volume":"25","author":"Ning","year":"2019","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0021","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s12967-021-03130-8","article-title":"Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART)","volume":"19","author":"Kron","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0022","article-title":"A RandomizEd PhAse II TrIal of Rilonacept in Subjects With Cardiac Sarcoidosis (REPAIR-CS)","author":"Rosenbaum","year":"2025","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0023","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.semarthrit.2019.11.004","article-title":"TNF-alpha inhibition for the treatment of cardiac sarcoidosis","volume":"50","author":"Baker","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0024","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.amjcard.2023.07.139","article-title":"Clinical response to tumor necrosis factor-alpha inhibitor therapy in the management of cardiac sarcoidosis","volume":"205","author":"Churchill","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0025","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0026","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.cardfail.2024.10.444","article-title":"Utility of mechanistic target of rapamycin inhibitors in cardiac sarcoidosis","volume":"31","author":"Richards","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0027","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cardfail.2021.07.008","article-title":"Rituximab for the treatment of refractory cardiac sarcoidosis: a single-center experience","volume":"28","author":"Elwazir","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0028","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.4049\/jimmunol.2101159","article-title":"Innate and adaptive immunity in noninfectious granulomatous lung disease","volume":"208","author":"McKee","year":"2022","journal-title":"J Immunol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0029","article-title":"Imbalanced distribution of regulatory T cells and Th17.1 cells in the peripheral blood and BALF of sarcoidosis patients: relationship to disease activity and the fibrotic radiographic phenotype","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0030","doi-asserted-by":"crossref","first-page":"21463","DOI":"10.3390\/ijms141121463","article-title":"Imbalance between Th17 and regulatory T-cells in sarcoidosis","volume":"14","author":"Huang","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1301991","article-title":"FOXP3+ regulatory T cells are associated with the severity and prognosis of sarcoidosis","volume":"14","author":"Patterson","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0032","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1164\/rccm.202306-1054OC","article-title":"Discovery of two novel immunoepitopes and development of a peptide-based sarcoidosis immunoassay","volume":"210","author":"Peng","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0033","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.3390\/ijms26146652","article-title":"The role of Cutibacterium acnes in the etiopathogenesis of sarcoidosis: current insights and future study directions","volume":"26","author":"Di Francesco","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0034","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0035","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.it.2020.01.007","article-title":"Sarcoidosis and the mTOR, Rac1, and autophagy triad","volume":"41","author":"Pacheco","year":"2020","journal-title":"Trends Immunol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0036","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00119-2019","article-title":"The NLRP3 inflammasome pathway is activated in sarcoidosis and involved in granuloma formation","volume":"55","author":"Huppertz","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0037","unstructured":"Kasahara K, Kobayashi K, Shikama Y, Yoneya I, Soezima K, Ide H, et al. Direct evidence for granuloma-inducing activity of interleukin-I induction of experimental pulmonary granuloma formation in mice by interleukin-I-coupled beads. Am J Pathol 1988;130:629\u201338."},{"key":"10.1016\/j.cardfail.2026.03.010_bib0038","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.119.007582","article-title":"Inflammasome formation in granulomas in cardiac sarcoidosis","volume":"12","author":"Kron","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0039","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0046-8177(92)90114-I","article-title":"Production of cytokines in sarcoid lymph nodes: preferential expression of interleukin-1\u03b2 and interferon-\u03b3 genes","volume":"23","author":"Devergne","year":"1992","journal-title":"Human Pathol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0040","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.44519","article-title":"HIF-1alpha regulates IL-1beta and IL-17 in sarcoidosis","volume":"8","author":"Talreja","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0041","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.4049\/jimmunol.1600258","article-title":"Dual Inhibition of Rip2 and IRAK1\/4 Regulates IL-1\u03b2 and IL-6 in sarcoidosis alveolar macrophages and peripheral blood mononuclear cells","volume":"197","author":"Talreja","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0042","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-72067-7","article-title":"Sarcoidosis exosomes stimulate monocytes to produce pro-inflammatory cytokines and CCL2","volume":"10","author":"Wahlund","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1227818","article-title":"Integrative single-cell analysis of cardiac and pulmonary sarcoidosis using publicly available cardiac and bronchoalveolar lavage fluid sequencing datasets","volume":"10","author":"Daoud","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0044","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0045","article-title":"Pathogenic pathways and therapeutic targets of inflammation in heart diseases: a focus on interleukin-1","volume":"54","author":"Del Buono","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0046","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1164\/ajrccm\/148.5.1378","article-title":"Interleukin-1 receptor antagonist expression in sarcoidosis","volume":"148","author":"Rolfe","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0047","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084148","article-title":"Myocardial accumulations of Reg3A, Reg3gamma and Oncostatin M are associated with the formation of granulomata in patients with cardiac sarcoidosis","volume":"22","author":"Gajawada","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0048","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.7150\/thno.109211","article-title":"Transcriptomic profiling of granuloma in patients with cardiac sarcoidosis","volume":"15","author":"Gajawada","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0049","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1164\/ajrccm.165.2.2106004","article-title":"Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis","volume":"165","author":"Hutyrov\u00c1","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0050","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/annrheumdis-2021-221801","volume":"81","author":"Romano","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0051","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamacardio.2022.2584","article-title":"Advances in imaging and targeted therapies for recurrent pericarditis: a review","volume":"7","author":"Kumar","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0052","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jamacardio.2023.4820","article-title":"Variants at the interleukin 1 gene locus and pericarditis","volume":"9","author":"Thorolfsdottir","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0053","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/FJC.0000000000001553","article-title":"Novel therapeutic insights into the treatment of pericarditis: targeting the innate immune system","volume":"83","author":"Vecchi\u00e9","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0054","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0055","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1177\/2047487319879534","article-title":"Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: the IRAP (International Registry of Anakinra for Pericarditis) study","volume":"27","author":"Imazio","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0056","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis","volume":"384","author":"Klein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0057","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.ijcard.2013.12.137","article-title":"Formation of the inflammasome in acute myocarditis","volume":"171","author":"Toldo","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0058","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.011729","article-title":"IL1RAP blockade with a monoclonal antibody reduces cardiac inflammation and preserves heart function in viral and autoimmune myocarditis","volume":"17","author":"Lema","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0059","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fimmu.2017.00131","article-title":"Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure","volume":"8","author":"Cavalli","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0060","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11739-023-03514-2","article-title":"Effectiveness and safety of IL1 inhibition with anakinra in chronic refractory idiopathic myocarditis","volume":"19","author":"Malandrino","year":"2023","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0061","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.acvd.2023.07.004","article-title":"Rationale and design of the ARAMIS trial: anakinra versus placebo, a double blind randomized controlled trial for the treatment of acute myocarditis","volume":"116","author":"Kerneis","year":"2023","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0062","first-page":"627","article-title":"In-perspective: the ARAMIS double-blind randomized placebo-controlled trial of anakinra for the treatment of acute myocarditis","volume":"12","author":"Morrow","year":"2023","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0063","article-title":"Desmoplakin cardiomyopathy presenting with recurrent myopericarditis responsive to interleukin-1 blockade","volume":"30","author":"Lopez","year":"2025","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0064","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.125.073919","article-title":"Prognostic role of myocarditis-like episodes and their treatment in patients with pathogenic desmoplakin variants","volume":"152","author":"Gasperetti","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0065","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/ni.3655","article-title":"Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression","volume":"18","author":"Linke","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0066","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semarthrit.2017.03.005","article-title":"Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients","volume":"47","author":"Jamilloux","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0067","unstructured":"Website NCTR. A multiple-dose, subject and investigator blinded, placebo-controlled, parallel design study to assess the efficacy, safety and tolerability of ACZ885 (canakinumab) in patients with pulmonary sarcoidosis 2019. https:\/\/www.novctrd.com\/ctrdweb\/trialresult\/trialresults\/pdf?trialResultId=17607."},{"key":"10.1016\/j.cardfail.2026.03.010_bib0068","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.123.011869","article-title":"Interleukin-1 blockade in cardiac sarcoidosis: a pilot study","volume":"16","author":"Kron","year":"2023","journal-title":"Circ Arrhythmia Electrophysiol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0069","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/08037059209077502","article-title":"Prospective Randomized Open Blinded End-point (PROBE) study. A novel design for intervention trials","volume":"1","author":"Hansson","year":"2009","journal-title":"Blood Pressure"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0070","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/00004872-200307000-00016","article-title":"Kempthorne-Rawson J. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements","volume":"21","author":"Smith","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0071","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1253\/circj.CJ-19-0508","article-title":"JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis\u2015digest version\u2015","volume":"83","author":"Terasaki","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0072","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s12350-017-0978-9","article-title":"Joint SNMMI\u2013ASNC expert consensus document on the role of 18F-FDG PET\/CT in cardiac sarcoid detection and therapy monitoring","volume":"24","author":"Chareonthaitawee","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0073","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00943-2025","article-title":"Pulmonary sarcoidosis clinical trial end-points: a Delphi study","volume":"66","author":"Baughman","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0074","article-title":"Test-retest repeatability for Fatigue Assessment Scale, Short-Form 6-Dimension and King's Sarcoidosis Questionnaire in people with sarcoidosis associated fatigue","volume":"40","author":"Ferris","year":"2023","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273126","article-title":"King\u2019s Sarcoidosis Questionnaire (KSQ) \u2013 validation study in Serbian speaking population of sarcoidosis patients","volume":"18","author":"Stjepanovic","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0076","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1164\/rccm.200211-1343OC","article-title":"The Sarcoidosis Health Questionnaire","volume":"168","author":"Cox","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152010","article-title":"The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time","volume":"55","author":"Stone","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.cardfail.2026.03.010_bib0078","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426001442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426001442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:58:06Z","timestamp":1783065486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916426001442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1071916426001442"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.03.010","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leveraging Interleukin-1 Blockade as a Therapeutic Strategy for Cardiac Sarcoidosis: Rationale and Design for the RandomizEd PhAse II TrIal of Rilonacept in Subjects With Cardiac Sarcoidosis (REPAIR-CS)","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}